We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » OIG ADVICE TO STATES MAY COST DRUGMAKERS MILLIONS
OIG ADVICE TO STATES MAY COST DRUGMAKERS MILLIONS
April 30, 2004
If states take the advice of the HHS Office of Inspector General (OIG) and start billing manufacturers for rebates on physician-administered drugs, drugmakers could have to fork over another $37 million a year or more in Medicaid drug rebates.